IL3RA and myelodysplastic syndrome: The first study demonstrated the possible safety and efficacy of AFM28, a novel bispecific innate cell engager (ICE®) targeting CD123 on MDS cells and CD16a on NK cells, with a higher stability compared with conventional Fc-optimized IgG1 antibodies [92].